Vical inks hep B research deal with AnGes MG; shares ahead 11% premarket

|About: Vical Incorporated (VICL)|By:, SA News Editor

Thinly traded nano cap Vical (NASDAQ:VICL) perks up 11% premarket on higher-than-normal volume in response to its announcement of a research collaboration with AnGes MG under which AnGes will fund preclinical research related to a development program targeting chronic hepatitis B infection. In exchange for the funding, AnGes will have the option to negotiate exclusive rights in Japan.